Honeycomb Biotechnologies

Honeycomb Biotechnologies is a private, pre-revenue platform company founded in 2017 and based in Cambridge, Massachusetts. The company's core innovation is the HIVE™ platform, which aims to simplify and improve single-cell analysis by enabling gentle capture, ambient storage, and sequencing of cells from any location, reducing data variability. While initially demonstrated in neuroscience applications like brain organoid research, the platform is positioned as a flexible tool with broad applicability across research and drug discovery. Honeycomb's business model likely involves selling instruments, consumables, and associated services to academic, biopharma, and clinical research customers.

HIVE™ Single Cell Solution: An integrated platform for gentle single-cell capture, ambient-temperature storage, and sequencing, enabling flexible scRNAseq workflows for complex samples.

Honeycomb competes in the single-cell sample prep and analysis market dominated by 10x Genomics (Chromium), BD (Rhapsody), and Bio-Rad (ddSEQ). Its differentiation lies in gentle capture and ambient storage, unlike the immediate processing required by most high-throughput droplet methods. It also competes with other niche players and startups focusing on specific sample types or microfluidic innovations.